What question did this study set out to answer?

This study aims to evaluate the effects of faricimab on anatomical and functional outcomes in patients with treatment-naïve neovascular age-related macular degeneration (nAMD).

April 28, 2026Open Access

Rapid Effects on Anatomical and Functional Outcomes following Upload with Faricimab in Treatment-Naïve nAMD: German Single-Center Study 45DRY

Puntos clave

This study aims to evaluate the effects of faricimab on anatomical and functional outcomes in patients with treatment-naïve neovascular age-related macular degeneration (nAMD).
Conducted a single-center trial in Germany.
Administered a four-dose faricimab upload according to the manufacturer's label.
Evaluated outcomes at week 16, focusing on anatomical drying and functional improvements.
Observations showed a substantial anatomical drying effect with marked reductions in central retinal thickness (CRT).
Best-corrected visual acuity (BCVA) improved significantly by week 16.
Findings align with post hoc analyses from the pivotal TENAYA and LUCERNE trials.

Resumen

In routine clinical practice, a four-dose faricimab upload per label at the time of study conduct led to a rapid and substantial anatomical drying effect at week 16 with improvement in BCVA and marked CRT reduction. These real-world findings confirm that faricimab rapidly and effectively reduces retinal fluid, in line with post hoc analyses of the pivotal TENAYA and LUCERNE trials.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Haase et al. (Sat,) studied this question.

synapsesocial.com/papers/69f04e08727298f751e7216d https://doi.org/https://doi.org/10.1007/s40123-026-01385-2

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo